Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMES: Ramucirumab + Gemcitabine in Mesothelioma
NCT03560973Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in malignant pleural mesothelioma (MPM), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Dec 2016; status: completed.
02
Drugs
ramucirumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03560973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560973.